p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
      Google Scholar   
Citation:
Urology vol 71 (5) 933-7
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
450  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
CA03927, CA31946, CA32291, CA33601, CA41287, CA60138, CA77406, CA77651  
Corr. Author:
 
Authors:
                     
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-159807, CALGB-9682
Phases:
2, N/A
Keywords:
Adenocarcinoma, Aged, Aged, 80 and over, Flutamide, Gonadotropin-Releasing Hormone, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Prospective Studies, Prostatic Neoplasms, Risk Factors, Tumor Suppressor Protein p53